Metformin in First Trimester: Safety Profile
Metformin is actually considered safe during the first trimester and does not need to be avoided—in fact, current evidence shows substantial safety data for first-trimester use with poor placental crossing due to lack of cation transporters during this period 1.
Key Evidence on First Trimester Safety
The premise of your question appears to be based on outdated concerns. The most recent 2025 guidelines explicitly state that "there are substantial safety data for metformin in the first trimester due to poor placental crossing from a lack of cation transporters in the first trimester" 1. This is a critical pharmacological distinction—metformin does not significantly cross the placenta during the first trimester, which is when organogenesis occurs and teratogenic risk would be highest.
Birth Defects Evidence
Multiple lines of evidence support first-trimester safety:
FDA labeling confirms that published post-marketing studies have not reported a clear association between metformin and major birth defects or miscarriage when used during pregnancy 2
A 2024 target trial emulation study of 12,489 pregnant women with type 2 diabetes found that continuing metformin plus adding insulin showed a risk ratio of 0.72 (95% CI: 0.51-1.09) for congenital malformations compared to switching to insulin alone—suggesting no increased risk and possibly even a protective effect 3
Meta-analysis of controlled studies in women with PCOS showed no statistically increased rate of major birth defects with first-trimester metformin exposure (OR 0.86,95% CI: 0.18-4.08) 4
Studies specifically examining first-trimester exposure found overall birth defect rates of 0.5-0.6% in metformin-exposed pregnancies, which is not elevated above background rates 4
When Concerns DO Arise (Second and Third Trimesters)
The actual concerns with metformin emerge after the first trimester, when placental cation transporters (particularly OCT3) develop and allow high maternal-to-fetal transfer in the second and third trimesters 5, 1. This is when metformin achieves fetal levels equal to or higher than maternal levels 5.
Specific Risks in Later Pregnancy
Small-for-gestational-age (SGA) risk is the primary concern, particularly in:
- Women with chronic hypertension and/or nephropathy who are already at risk for fetal growth restriction 1
- The MiTY trial showed 14.4% SGA rate with metformin plus insulin versus 2% with insulin alone (p < 0.01) 1
Long-term offspring concerns include:
- Potential altered body composition with increased childhood BMI and adiposity at ages 5-10 years in some cohorts 5, 1
- Possible effects on skeletal muscle and kidney development based on primate models 1
- These effects are attributed to metformin's actions on AMPK, mitochondrial function, and mTOR pathways during fetal development 1
Clinical Algorithm for Metformin Use in Pregnancy
For women already on metformin before pregnancy:
- Continue through first trimester if needed for glycemic control—this is safe 1
- Reassess at end of first trimester whether to continue or transition to insulin based on individual factors 1
Avoid metformin continuation if:
- Chronic hypertension present 1
- Nephropathy/kidney disease present 1
- Evidence of fetal growth restriction 6, 7
Consider continuing metformin if:
- Extreme insulin resistance requiring very high insulin doses 1
- Significant barriers to insulin use (cost, access, adherence) 1
- Patient strongly prefers to minimize insulin injections AND has no contraindications 1
Common Pitfall to Avoid
The major pitfall is confusing first-trimester safety with later pregnancy concerns. The biological mechanism differs dramatically by trimester due to placental transporter expression. First-trimester exposure carries minimal risk because metformin doesn't cross the placenta effectively during organogenesis. The concerns about SGA, altered fetal programming, and childhood obesity relate to second and third trimester exposure when placental transfer is high 5, 1.
Bottom line: The question "why not to give metformin in first trimester" is based on a misconception. Current 2025 guidelines from both the American Diabetes Association and the Endocrine Society/European Society of Endocrinology joint guideline support first-trimester safety, with the caveat that metformin should be used judiciously throughout pregnancy based on individual maternal and fetal factors 5, 1.